Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab
Authors
- Farhad Ravandi (ORCID: https://orcid.org/0000-0002-7621-377X)
- Ken Furudate
- Fadi Haddad (ORCID: https://orcid.org/0000-0002-9702-8485)
- Nitin Jain (ORCID: https://orcid.org/0000-0003-0114-8384)
- Elias Jabbour (ORCID: https://orcid.org/0000-0003-0946-1519)
- Lewis Nasr (ORCID: https://orcid.org/0000-0003-3202-4878)
- Rebecca Garris (ORCID: https://orcid.org/0000-0001-8009-5529)
- Koichi Takahashi (ORCID: https://orcid.org/0000-0002-8027-9659)
- Sanam Loghavi (ORCID: https://orcid.org/0000-0001-8980-3202)
- Jayastu Senapati (ORCID: https://orcid.org/0000-0002-6831-2567)
- Omer Karrar (ORCID: https://orcid.org/0000-0001-6026-4073)
- Nicholas James Short (ORCID: https://orcid.org/0000-0002-2983-2738)
- Hagop Kantarjian
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1186/s13045-025-01709-y
- Citations
- 9
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 16.91
Funders
- Amgen
- National Institutes of Health
- Takeda Oncology
- National Cancer Institute